Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.62 |
| ▸ | CTSS | P25774 | 3/20 | 0.62 |
| ▸ | CTSK | P43235 | 4/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | ECE1 | P42892 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5973119 | 0.96 | CTSL (0.58) | CTSLCTSSCTSKSIRT2SIRT1 | |
| SCHEMBL10606513 | 0.87 | CTRB1 (0.52) | CTSLCTSSCTSKCTRB1ATM | |
| SCHEMBL6605708 | 0.87 | CTRB1 (0.52) | CTSLCTSSCTSKCTRB1ATM | |
| SCHEMBL28370653 | 0.86 | CTSL (0.62) | CTSLCTSSCTSKSIRT2SIRT1 | |
| SCHEMBL3941408 | 0.85 | CTSK (0.50) | CTSLCTSSCTSKSIRT2SIRT1 | |
| SCHEMBL2472067 | 0.85 | SYK (0.56) | CTSLCTSSCTSKCTRB1ATM | |
| SCHEMBL6054417 | 0.85 | SYK (0.56) | CTSLCTSSCTSKCTRB1ATM | |
| SCHEMBL19519898 | 0.85 | CTSL (0.59) | CTSLCTSSCTSKSIRT2SIRT1 | |
| SCHEMBL8080975 | 0.84 | CTSL (0.61) | CTSLCTSSCTSKSIRT2SIRT1 | |
| SCHEMBL5501379 | 0.84 | CTSL (0.61) | CTSLCTSSCTSKSIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958878-B2 | Therapeutic agent for glycogen storage disease type IA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-04-16 | — | — | US | disclosed |
| CN-115976028-A | Remedies for glycogen disease type Ia | 第一三共株式会社 | 2023-04-18 | — | — | CN | disclosed |
| EP-4029520-A1 | GALNAC-OLIGONUCLEOTIDE CONJUGATE FOR LIVER-TARGETED DELIVERY USE, AND METHOD FOR PRODUCING SAME | Daiichi Sankyo Company, Limited (JP) | 2022-07-20 | — | — | EP | disclosed |
| CN-114616332-A | GalNAc-oligonucleotide conjugates for delivery to liver and methods of making the same | 第一三共株式会社 | 2022-06-10 | — | — | CN | disclosed |
| WO-2021049504-A1 | GALNAC-OLIGONUCLEOTIDE CONJUGATE FOR LIVER-TARGETED DELIVERY USE, AND METHOD FOR PRODUCING SAME | 第一三共株式会社 | 2021-03-18 | — | — | WO | disclosed |
| EP-3763815-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | Daiichi Sankyo Company, Limited (JP) | 2021-01-13 | — | — | EP | disclosed |
| US-20200407394-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-12-31 | — | — | US | disclosed |
| CN-111511915-A | Remedies for glycogen disease type Ia | 第一三共株式会社 | 2020-08-07 | — | — | CN | disclosed |
| WO-2019172286-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | 第一三共株式会社 | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407394-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | G6PC1, GAA, GBA3 | CTSL 3382/4885CTSS 3162/4885CTSK 3398/4885 |
| US-11958878-B2 | Therapeutic agent for glycogen storage disease type IA | G6PC1, GAA, GBA3 | CTSL 3511/4885CTSS 3327/4885CTSK 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.